Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Escape Clear all
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

NCT03747939
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Apremilast (CC-10004), Apremilast (CC-10004) Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Covina, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

NCT00265083
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
golimumab, Golimumab (CNTO 148); placebo
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Response to Acute Exercise in Eating Disorders

NCT06213883
View directory record Official record
Conditions
Eating Disorders
Interventions
Biobehavioral Response to in-lab exposure to physical activity
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years to 25 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 7:59 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional

Modulating Escape Using Focused Ultrasound

NCT06273904
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Active transcranial focused ultrasound (tFUS), Sham transcranial focused ultrasound (tFUS)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 19, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional

Modulating Anxious Coping

NCT04824105
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326298
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 19, 2026, 7:59 AM EDT
Withdrawn Not applicable Interventional

Protect Yourself: Abuse Prevention for People With Intellectual Disabilities

NCT03998605
View directory record Official record
Conditions
Abuse Prevention
Interventions
Abuse Prevention Program, Control Condition
Behavioral
Lead sponsor
Double S Instructonal Systems
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00361335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab, Methotrexate, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
20
States / cities
Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Protein Supplementation on Lean Body Mass Recovery From Extreme Military Training

NCT02057094
View directory record Official record
Conditions
Military Operational Stress Reaction, Malnutrition (Calorie), Weight Loss, Muscle Wasting
Interventions
Protein, High-Protein, and Control
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Marine Corps Base Camp Lejeune, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 19, 2026, 7:59 AM EDT
Not listed Not applicable Interventional

EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE-MeVO Trial)

NCT05151172
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
endovascular thrombectomy (EVT), Standarad medical care
Device · Other
Lead sponsor
Dr. Michael D Hill
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • San Francisco, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 19, 2026, 7:59 AM EDT
Recruiting Phase 2 Interventional

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
APG777
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

D-cycloserine and Treatment of Feeding Disorders

NCT01923896
View directory record Official record
Conditions
Feeding Disorders, Specific Phobia
Interventions
Behavioral Intervention, d-cycloserine (DCS), Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Months to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 19, 2026, 7:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

NCT02437162
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ESCAPE Kits for Elopement Prevention in Children With Autism

NCT07225907
View directory record Official record
Conditions
Autism Spectrum Disorder, Child Safety, Caregiver Stress
Interventions
Elopement Prevention Kits
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
4 Years to 11 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information

NCT06193070
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Educational Intervention, Interview, Survey Administration, Telemedicine
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 19, 2026, 7:59 AM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)

NCT00299546
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

NCT00386243
View directory record Official record
Conditions
Low Back Pain, Pain, Pain, Intractable
Interventions
Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

Virtual Reality for Pain in Acute Orthopedic Injuries

NCT05552430
View directory record Official record
Conditions
Injuries, Injury Arm, Injury;Sports, Injury, Knee, Injury Wrist, Injury, Ankle, Injury Foot, Injury, Hand, Injury Finger, Injury Leg
Interventions
RelieveVRx
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 19, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional

A Virtual Reality Mindfulness Application for Aggression in Schizophrenia

NCT07434479
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
Interventions
Mindfulness-Based Virtual Reality Intervention
Other
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 19, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

NCT01077362
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
placebo, ustekinumab 45 mg, ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 19, 2026, 7:59 AM EDT